ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)


LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE: ADCT) announced today that ZYNLONTA® (Loncastuximab tesirin-lpyl) and camidanlumab tesirine (Cami) have been accepted for presentation at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022) to be held September 28-October 1, 2022 in Houston, Texas.

We look forward to presenting the encouraging initial run-in safety results from our Phase 3 LOTIS-5 clinical trial evaluating ZYNLONTA in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma at SOHO 2022,” said Joseph Camardo, MD, Chief Medical Officer of ADC Therapeutics. “This is one of several clinical trials of ZYNLONTA in combination with other drugs to evaluate ZYNLONTA in previous lines of treatment. ”

LOTIS-5 First Security Run-In Results

LOTIS-5 is a Phase 3, randomized, open-label, two-part, two-arm, multicenter study of loncastuximab tesirine in combination with rituximab (Lonca-R) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). ). Twenty patients were enrolled in Part 1 of a non-randomized safety run-in. In Part 2, approximately 330 patients will be randomized 1:1 to receive Lonca-R or rituximab-gemcitabine-oxaliplatin (R-GemOx).

The 20 patients in the safety run-in had a median age of 74.5 years (range 35-93) and received a median of 1 prior therapy (range 1-6). From February 28, 2022, data cut-off:

  • The overall response rate after central review was 15/20 (75%). A total of 8/20 (40%) and 7/20 (35%) patients achieved a complete response and partial response, respectively.

  • The most common TEAEs of all grades, regardless of association with study treatment, were rash (5th [25%]), tiredness (4 [20%]) and elevated gamma-glutamyl transferase (4th [20%]). The most common grade ≥ 3 TEAEs were elevated gamma-glutamyltransferase (3rd [15%]), increased alanine aminotransferase (2nd [10%]) and neutropenia (2nd [10%]).

This data is presented in the following poster:

First run-in safety results of the phase 3 study LOTIS-5: Novel combination of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with r/r DLBCL

Poster number: ABCL-320

Details of ADC Therapeutics’ other poster presentations:

A phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large B-cell lymphoma (DLBCL) (LOTIS-9) (Encore data, first time presentation )

Poster number: ABCL-272

Health-related quality of life and tolerability in patients with/without skin toxicity during treatment with loncastuximab tesirine in a phase 2 clinical study (LOTIS-2)

Poster number: ABCL-316

Long-term survival prognosis of loncastuximab tesirine-treated patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (Encore data, presented for the first time)

Poster number: ABCL-334

Camidanlumab Tesirin: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL) (encore)

Poster number: HL-339

All posters will be presented on Wednesday, September 28 from 5:05pm to 6:30pm CT in the Ballroom of Americas on Level 2 of the Hilton-Americas Houston. The posters will remain in the poster hall for viewing all day on Thursday and Friday. Online access to posters for registered attendees begins Thursday, September 29th.

ADC Therapeutics Oral Presentation Details:

Camidanlumab Tesirin: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL) (encore)

Date and Time: Friday, September 30, 5:48-5:58 PM CT

Location: Grand Ballroom GL, 4thth floor

Moderator: Alex Herrera, MD, City of Hope, Duarte, California, USA

Session XII: Hodgkin Lymphoma

About ZYNLONTA® (Loncastuximab tesirine lpyl)

CYNLONTA® is an antibody-drug conjugate (ADC) directed against CD19. Once ZYNLONTA is bound to a CD19-expressing cell, it is internalized by the cell where enzymes release a pyrrolobenzodiazepine (PBD) payload. The strong payload binds to the DNA minor groove with little distortion and remains less visible to DNA repair mechanisms. This ultimately leads to cell cycle arrest and tumor cell death.

The US Food and Drug Administration (FDA) has approved ZYNLONTA (loncastuximab-tesirin-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL unless otherwise stated, DLBCL arising from low-grade lymphoma and also from high-grade B-cell lymphoma. The study included a broad spectrum of heavily pretreated patients (a median of three prior lines of therapy) with difficult-to-treat conditions, including patients who failed first-line therapy, patients who failed all prior lines of therapy, and patients with double/triple hit genetics and patients who had received stem cell transplantation and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is being approved by the FDA under accelerated approval based on overall response rate, and continued approval for this indication may be subject to verification and characterization of clinical benefit in a confirmatory study.

ZYNLONTA is also being investigated as a therapeutic option in combination studies in other B-cell malignancies and previous lines of therapy.

About camidanlumab tesirine (Cami)

Camidanlumab tesirine (Cami) is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody conjugated to CD25 (HuMax®-TAC licensed from Genmab A/S) conjugated to the pyrrolobenzodiazepine (PBD) dimer payload, tesirine. Once bound to a CD25-expressing cell, Cami is internalized into the cell where enzymes release the PBD-based payload and kill the cell. This applies both to CD25-expressing tumor cells and to CD25-expressing Tregs. Intratumoral release of their PBD payload can also cause bystander killing of neighboring tumor cells, and PBDs have also been shown to induce immunogenic cell death. All of these properties of Cami can enhance immune-mediated antitumor activity.

Cami is being evaluated in a pivotal Phase 2 clinical trial in patients with relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial as monotherapy and in combination with pembrolizumab in solid tumors.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation targeted antibody-drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ ZYNLONTA (loncastuximab-tesirin-lpyl) anti-CD19 ADC is FDA-approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being investigated in a pivotal Phase 2 study in relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical study in various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has several ADCs in ongoing clinical and pre-clinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, with offices in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the company Twitter and LinkedIn.

CYNLONTA® is a registered trademark of ADC Therapeutics SA.





Source link

Also Read :  CRV's $1.5B investment will include digital health